News for Sanofi Stock (SNY)

MeiraGTx shares jump as Sanofi invests in gene therapy

Market Watch • 10/30/23

Sanofi (SNY) Q3 2023 Earnings Call Transcript

Seeking Alpha • 10/27/23

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

Zacks Investment Research • 10/27/23

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff

InvestorPlace • 10/27/23

Sanofi Crashes 16% As Third Quarter Comes In Light Ahead Of Spinoff

Investors Business Daily • 10/27/23

Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes

Market Watch • 10/27/23

Shares of Amazon, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move

Market Watch • 10/27/23

Sanofi takes page from rivals' separation playbook

Reuters • 10/27/23

Sanofi plans to spin out its consumer health division

Proactive Investors • 10/27/23

Sanofi to create its own Haleon, Kenvue as its stock price tumbles

Invezz • 10/27/23

Sanofi: considering consumer unit listing from late next year

Reuters • 10/27/23

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

GlobeNewsWire • 10/27/23

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

GlobeNewsWire • 10/22/23

Sanofi seeing 'unprecedented' demand for RSV therapy

Reuters • 10/20/23

GoodRx to offer Sanofi's insulin injection for only $35

Reuters • 10/19/23

Sanofi to offer insulin product for $35 to all Americans through GoodRx

CNBC • 10/19/23

GoodRx Announces New Way for Consumers to Access Sanofi's Lantus for $35 at Over 70,000 Pharmacies Nationwide

Business Wire • 10/19/23

Press Release: Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio

GlobeNewsWire • 10/19/23

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

GlobeNewsWire • 10/18/23

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

GlobeNewsWire • 10/13/23

Sanofi reaps rewards of immunology investment with eczema results

Market Watch • 10/13/23

2 Surefire Stocks That Could Make You Richer

The Motley Fool • 10/11/23

BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics

Business Wire • 10/10/23

Nobel for mRNA: Which other biotech stocks might be overlooked?

Proactive Investors • 10/06/23

Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?

Zacks Investment Research • 10/05/23